<DOC>
	<DOC>NCT01977768</DOC>
	<brief_summary>The purpose of the study is to identify optimally effective dose of whole-cell, heat-killed Mycobacterium vaccae formulated as a pill and consequently carry out multi-country, placebo-controlled, randomized Phase III trial in patients with drug-sensitive, multi-drug resistant (MDR-TB) and TB-HIV.</brief_summary>
	<brief_title>TB Immunotherapy Trial With Heat-killed M. Vaccae</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>confirmed diagnosis of TB sputum smear positive pregnant likely to be noncompliant due to drug and/or alcohol abuse mentally unfit to comply with treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>M. vaccae</keyword>
	<keyword>TB</keyword>
	<keyword>MDR-TB</keyword>
	<keyword>V7-immunitor</keyword>
</DOC>